CaptureSelect™ Biotin Anti-AAVX Conjugate

CaptureSelect Biotin Anti-AAVX Conjugate consists of a 14 kDa recombinant single domain antibody fragment that specifically binds with high affinity and selectivity to native and recombinant adeno-associated virus (AAV) particles of various serotypes.

The anti-AAVX affinity ligand has demonstrated binding reactivity towards a large set of different AAV serotypes including AAV1 to AAV8, and AAVrh10, indicating that an even broader range of AAV serotypes could potentially be recognized and detected. The affinity ligand is chemically conjugated to biotin via a spacer that retains the binding reactivity of the ligand when used in combination with streptavidin-based conjugates or streptavidin pre-coated surfaces.

This conjugate enables the detection, quantitation, and characterization of native and recombinant AAV virus particles. Applications for CaptureSelect Biotin Anti-AAVX Conjugate include ELISA, immunoprecipitation with streptavidin-coupled Dynabeads, Gyrolab™-based immunoassays, and use with label-free detection platforms such as those based on surface plasmon resonance (Biacore™ and IBIS-MX96 systems) and bio-layer interferometry (ForteBio™ Octet™ systems).

Animal origin statement

CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (V_HH) created by a proprietary technology. The V_HH affinity ligand is a 12–15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).